æ€ç©ç±æ¥ãŠã€ã«ã¹ã®æ®»ïŒVLPïŒã®è¡šé¢äžã«ç åæ§ãŠã€ã«ã¹ç±æ¥ã®ããã±ã質ãçºçŸãããã¯ã¯ãã³æè¡ãæã€ãã€ãªãã³ãã£ãŒãæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã¯ã¯ãã³ã®éçºãè¡ã£ãŠãããç°èŸºäžè±è£œè¬ã®åäŒç€Ÿã
ããŒã ããŒãžïŒhttps://www.medicago.com/en/
èæ¯ãšãã¯ãããžãŒïŒ
ã»æ°åã³ãããŠã€ã«ã¹SARS-CoV-2ã®ã¯ã¯ãã³éçºãæ±ããããŠãããäžçäžã®è£œè¬äŒæ¥ããã€ãªãã³ãã£ãŒãããŸããŸãªã¢ãããŒãã§ã¯ã¯ãã³éçºãè¡ã£ãŠãããã倧ãŸãã«ä»¥äžã®ãããªã¢ãããŒãã«ãªãã
ã»RNAã¯ã¯ãã³
SARS-CoV-2ã®ããã±ã質ãçºçŸããRNAã䜿ã£ãã¯ã¯ãã³ãå€ãã®å ŽåãSARS-CoV-2ã®èè¡šé¢ã«ããã¹ãã€ã¯ããã±ã質ãçºçŸããïŒSARSãMERSã®ã¯ã¯ãã³éçºã«ãããŠã¹ãã€ã¯ããã±ã質ãæåãšããã®ããããšããå è¡ç¥èŠããïŒãååŠä¿®é£Ÿãæ¹å€ããRNAãçšããããšã§çäœå ã§å®å®åããããéºäŒåå°å ¥å¹çãäžããããã工倫ããããŠããå Žåãå€ããRNAã¯çŽ°èèãééããŠçŽ°è質ãŸã§å°éããã°çºçŸããïŒDNAã¯çŽ°èæ žãŸã§å°éãããå¿ èŠãããïŒãå®å®æ§ãéºäŒåå°å ¥å¹çãäžããããã«è質ããç²åãªã©ã«å°å ¥ããã±ãŒã¹ãèããããã
ã¡ãªãã RNAã¯èªç¶å ç«ã掻æ§åããäœçšãæã€ãçç©è£œå€ã§ã¯ãªãããã«è£œé ã簡䟿ïŒãã ãæ¿èªæžã¿ã¯ã¯ãã³ããªãããèªå¯æžã¿è£œé æœèšããŸã ãªãïŒãç 究ã補é ã茞éãä¿åãæäžæã«ç åæ§ãŠã€ã«ã¹ãæ±ãå¿ èŠããªãã
ãã¡ãªãã å®çšåãããŠããRNAã¯ã¯ãã³ããªããããå¹æãå®å šæ§ãæªç¥æ°ãšãã課é¡ãããã
ã»DNAã¯ã¯ãã³
SARS-CoV-2ã®ããã±ã質ãçºçŸããDNAã䜿ã£ãã¯ã¯ãã³ãå€ãã®å ŽåãSARS-CoV-2ã®èè¡šé¢ã«ããã¹ãã€ã¯ããã±ã質ãçºçŸããïŒSARSãMERSã®ã¯ã¯ãã³éçºã«ãããŠã¹ãã€ã¯ããã±ã質ãæåãšããã®ããããšããå è¡ç¥èŠããïŒãDNAã¯çŽ°èæ žãŸã§å°éãããå¿ èŠãããïŒRNAã¯çŽ°èèãééããŠçŽ°è質ãŸã§å°éããã°çºçŸããïŒãå®å®æ§ãéºäŒåå°å ¥å¹çãäžããããã«è質ããç²åãªã©ã«å°å ¥ããã±ãŒã¹ãèããããã
ã¡ãªãã çç©è£œå€ã§ã¯ãªãããã«è£œé ã簡䟿ã§å€§é補é ããããïŒãã ãæ¿èªæžã¿ã¯ã¯ãã³ããªãããèªå¯æžã¿è£œé æœèšããŸã ãªãïŒãç 究ã補é ã茞éãä¿åãæäžæã«ç åæ§ãŠã€ã«ã¹ãæ±ãå¿ èŠããªããåžžæž©ä¿åå¯èœã
ãã¡ãªãã ã¯ã¯ãã³ãæ žãŸã§ééããããã«ç¹æ®ãªæäžããã€ã¹ãå¿ èŠãšãªãã
ã»ãªã³ã³ããã³ãããã±ã質ã¯ã¯ãã³
SARS-CoV-2ã®ããã±ã質ã䜿ã£ãã¯ã¯ãã³ãå€ãã®å ŽåãSARS-CoV-2ã®èè¡šé¢ã«ããã¹ãã€ã¯ããã±ã質ãçšããïŒSARSãMERSã®ã¯ã¯ãã³éçºã«ãããŠã¹ãã€ã¯ããã±ã質ãæåãšããã®ããããšããå è¡ç¥èŠããïŒããã®ãŸãŸã§æåãšãªãã
ã¡ãªãã ãªã³ã³ããã³ãããã±ã質ã¯ã¯ãã³æè¡ã¯ãã§ã«èªå¯æžã¿ã®æè¡ã»è£œé èšåãããïŒããã¥ããŠã€ã«ã¹ã䜿ã£ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãããããããŒããŠã€ã«ã¹ã¯ã¯ãã³ããé µæ¯ã䜿ã£ãBåèçãŠã€ã«ã¹ã¯ã¯ãã³ãããããããŒããŠã€ã«ã¹ã¯ã¯ãã³ïŒãç 究ã補é ã茞éãä¿åãæäžæã«ç åæ§ãŠã€ã«ã¹ãæ±ãå¿ èŠããªããå ç«åæ§ãåŒãèµ·ããã¢ãžã¥ãã³ãã䜿ããã
ãã¡ãªãã æ£ããç«äœæ§é ïŒãã©ãŒã«ãã£ã³ã°ïŒã®ããã±ã質ã確èªãå¿ èŠã倧é補é ã«æéããããã
ã»ãŠã€ã«ã¹ãã¯ã¿ãŒããŒã¹ã¯ã¯ãã³
SARS-CoV-2ã®ããã±ã質ãçºçŸãããŠã€ã«ã¹ãã¯ã¿ãŒã䜿ã£ãã¯ã¯ãã³ãå€ãã®å ŽåãSARS-CoV-2ã®èè¡šé¢ã«ããã¹ãã€ã¯ããã±ã質ãçºçŸããïŒSARSãMERSã®ã¯ã¯ãã³éçºã«ãããŠã¹ãã€ã¯ããã±ã質ãæåãšããã®ããããšããå è¡ç¥èŠããïŒã
ã¡ãªããããŠã€ã«ã¹ãã¯ã¿ãŒããŒã¹ã¯ã¯ãã³ã¯ãã§ã«èªå¯æžã¿ã®æè¡ã»è£œé èšåãããïŒãšãã©ãŠã€ã«ã¹ã¯ã¯ãã³ã®vesicular stomatitis virusãã¯ã¿ãŒã®ã¿ïŒç 究ã補é ã茞éãä¿åãæäžæã«ç åæ§ãŠã€ã«ã¹ãæ±ãå¿ èŠããªããéèšåºè©Šéšãèšåºè©Šéšã§éåžžã«æå¹ãªããŒã¿ãåºãŠããã
ãã¡ãªããããŠã€ã«ã¹ãã¯ã¿ãŒãã®ãã®ãæåãšãªã£ãŠããŸããã¯ã¯ãã³å¹æã«æªåœ±é¿ãã§ãå¯èœæ§ãããã
ã»åŒ±æ¯åã¯ã¯ãã³
SARS-CoV-2ã®åŒ±æ¯æ ªãã®ãã®ã䜿ã£ãã¯ã¯ãã³ïŒåèïŒã
ã¡ãªãããããªãªã¯ã¯ãã³ãªã©ã§ãã§ã«åºã䜿ãããŠããæ¹æ³ã§ãããé²ãæ¹ã確ç«ããŠããããã§ã«ãã補é èšåãæµçšå¯èœã§ããã
ãã¡ãªããã匱æ¯æ ªã®ã¯ããŒã³åãå¿ èŠã§ãéåžžã«æéãšæéããããããŠã€ã«ã¹ã®å¢ããæ¹ã確ç«ããŠããªããå®å šæ§ã«é¢ããè©Šéšã®èŠæ±åºŠãé«ããªãã
ã»äžæŽ»æ§åã¯ã¯ãã³
SARS-CoV-2ã殺ããŠæ¯æ§ããªãããã¯ã¯ãã³ïŒåèïŒã
ã¡ãªãããã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãªã©ã§ãã§ã«åºã䜿ãããŠããæ¹æ³ã§ãããé²ãæ¹ã確ç«ããŠããããã§ã«ãã補é èšåãæµçšå¯èœã§ãããã¢ãžã¥ãã³ããçšããŠå ç«åæ§ãäžæãããããšãã§ãããSARS-CoV-1ãŠã€ã«ã¹ã®ã¯ã¯ãã³ãšããŠãã§ã«ããã§è©Šãããããšãããã
ãã¡ãªããã補é æã«ç åæ§ã®ãŠã€ã«ã¹ã倧éã«æ±ãå¿ èŠããããªã¹ã¯ããããäžæŽ»æ§åŠçã«ããæåæ§ãå€ãã£ãŠããªããïŒæåããã±ã質ã®ç«äœæ§é ãå€ãã£ãŠããŸã£ãŠããªããïŒç¢ºèªããå¿ èŠãããã
ã»ä»å玹ä»ããMedicagoã¯ãSARS-CoV-2ã¯ã¯ãã³ã®éçºãè©Šã¿ãŠãããã€ãªãã³ãã£ãŒã§ãããæ€ç©ç±æ¥ã®ãŠã€ã«ã¹ã®æ®»ã ãïŒVirus-Like ParticleïŒVLPïŒã䜿ããSARS-CoV-2ã®ã¹ãã€ã¯ããã±ã質ãVLPã®æ®»ã®äžã«çºçŸãããããã«æäžããããšã§SARS-CoV-2ã®å ç«ãèªå°ããæè¡ã§ãããVLPã¯ããã«å¯ŸããŠæææ§ã¯ãªãããå ç«ç³»ã«å¯ŸããŠæåæ瀺ã§ããå¹ççãªæ¹æ³ã§ãããVLPã¯ãŠã€ã«ã¹ã®åœ¢ç¶ãšäŒŒã圢ç¶ãããŠãããããå ç«ç³»ããèªèããããããšã®ããšã
ã»VLPããŒã¹ã¯ã¯ãã³ã®æåæ¢çŽ¢ã®ããã®ã¹ã¯ãªãŒãã³ã°ç³»ãšããŠVLPExpressâ¢ãšããã·ã¹ãã ãæ§ç¯ããŠãããïŒé±éã§ïŒïŒïŒåã®ç°ãªãæåãçºçŸãããæ¢çŽ¢ç 究ãå¯èœãã¯ã¯ãã³ã®æ¢çŽ¢ç 究ã·ã¹ãã ãçšããŠãæäœå»è¬åã®æ¢çŽ¢ãè¡ã£ãŠãããææçããããªããªã€ãäŸåçãªã©ã®æ²»çè¬éçºãç®æããŠããã
ã»ãããã®ç¬èªæè¡ã¯ææç以å€ã®å¹ åºãçŸæ£é åã®æ²»çè¬ãžå¿çšå¯èœã§ãããããå ç«æ²»çè¬éçºãªã©ãèŠéã«å ¥ããŠããã
ã»æ€ç©ç±æ¥ã®ãŠã€ã«ã¹ãçšããŠãããããæ€ç©ã宿䞻ãšããŠçšããŠVLPãå¢å¹ ããŠè£œé ããïŒProficia®ãã¯ãããžãŒïŒãé¶åµãçšããã¯ã¯ãã³è£œé ãªã©åŸæ¥ã®æ¹æ³ã«æ¯ã¹ãŠè¿ éãã€å€§èŠæš¡ãªè£œé ãå¯èœãšã®ããšã
ãã€ãã©ã€ã³ïŒè©³çŽ°æªé瀺ïŒïŒ
ã»ã³ãããŠã€ã«ã¹ã¯ã¯ãã³
SARS-CoV-2ã®ããã±ã質ã殻衚é¢ã«çºçŸããæ€ç©ç±æ¥VLPã¯ã¯ãã³ã
éçºäžã®é©å¿ç
ã»åèšåºç 究段é
COVID-19
ã»ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã¯ã¯ãã³
ã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã®æ®»è¡šé¢äžã«çºçŸããŠããããã°ã«ããã³ããã±ã質ã殻衚é¢ã«çºçŸããæ€ç©ç±æ¥VLP4䟡ã¯ã¯ãã³ãããŸããŸãªã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ã«é©å¿ã§ãããšã®ããšã
éçºäžã®é©å¿ç
ã»Phase III
å£ç¯æ§ã€ã³ãã«ãšã³ã¶ææç
ã»Phase II
ãã³ãããã¯ã€ã³ãã«ãšã³ã¶ææç
ã»ãã¿ãŠã€ã«ã¹ã¯ã¯ãã³
ãã¿ãŠã€ã«ã¹ã®ããã±ã質ã殻衚é¢ã«çºçŸããæ€ç©ç±æ¥VLPã¯ã¯ãã³ãç°èŸºäžè±è£œè¬ãšã®å ±åç 究éçºã
éçºäžã®é©å¿ç
ã»Phase I
ãã¿ãŠã€ã«ã¹ææç
ã»ãããŠã€ã«ã¹ã¯ã¯ãã³
ãããŠã€ã«ã¹ã®ããã±ã質ã殻衚é¢ã«çºçŸããæ€ç©ç±æ¥VLPã¯ã¯ãã³ã
éçºäžã®é©å¿ç
ã»åèšåºç 究段é
ãããŠã€ã«ã¹ææç
ã»ã³ãããŠã€ã«ã¹æäœå»è¬å
詳现äžæãæ¢çŽ¢ç 究段éã
ã³ã¡ã³ãïŒ
ã»Medicagoã®VLPã¯æ€ç©ç±æ¥ãŠã€ã«ã¹ãããŒã¹ãšããŠããããã®ããããã®çŽ°èã«åã蟌ãŸããå¯èœæ§ã¯ããŒãªãã ãããåç©ç±æ¥ãŠã€ã«ã¹ãçšããVLPããDDSæè¡ãšããŠéçºããŠããäŒç€Ÿãããããããã¯ãããã®çŽ°èã«åã蟌ãŸããŠäžèº«ãããªããªãŒãããããªVLPãç®æããŠãããMedicagoã®VLPã¯ãã®ãããªçšéã§ã¯äœ¿ãããã¯ã¯ãã³ã«ç¹åãã䜿ãæ¹ã«ãªãã®ã ããã
ã»åŒ±æ¯åã¯ã¯ãã³ã§ã¯ã€ã³ãã®äŒç€ŸãSARS-CoV-2ã®åŒ±æ¯æ ªãåé¢ããŠéçºããŠããïŒåèïŒãä»ã®ææçã®ã¯ã¯ãã³ã®è©±ã ããäžæŽ»æ§åã¯ã¯ãã³ã§ãææãããããªçç¶ãåºãŠããŸã人ãããã匱æ¯æ ªã§éçåããŠããŸãããšã¯ãªãã®ã ãããïŒ
ããŒã¯ãŒãïŒ
ã»ã¯ã¯ãã³
ã»æåçºçŸVirus-Like ParticleïŒVLPïŒ
ã»æ°åã³ãããŠã€ã«ã¹ææçCOVID-19
ã»ã€ã³ãã«ãšã³ã¶
å 責äºé ïŒ
æ£ç¢ºãªæ å ±æäŸãå¿ãããŠããŸãããæ¬å 容ã«åºã¥ããåŠäœãªãã¢ã¯ã·ã§ã³ã«å¯ŸããŠãå 補è¬ç 究å¡ã±ã³ã¯è²¬ä»»ããšããŸããããããããé¡ãããŸãã